BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 14, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2004

View Archived Issues

New polymeric cytotoxic agents developed by Sankyo scientists

Read More

Novel antitumor protein kinase inhibitors under study at Abbott

Read More

Novel SGLT inhibitors prepared and tested by Yamanouchi and Kotobuki scientists

Read More

Novartis claims aldosterone synthase inhibitors and their use

Read More

Novel antifungal agents isolated and tested at Meiji Seika

Read More

Novel tachykinin NK1 antagonists covered by Tanabe Seiyaku patent

Read More

Exercise and metformin improve cardiovascular parameters in HIV-infected patients

Read More

Safety and pharmacokinetics of a human monoclonal antibody for anthrax

Read More

Improved diagnosis of stenosis achieved with the contrast agent MS-325

Read More

Diagnostic benefits of the contrast agent SHL-643A in magnetic resonance imaging

Read More

Novel selective TGF-beta inhibitor by GlaxoSmithKline

Read More

PARP inhibitor HO-3089 demonstrates both cardioprotective and antithrombotic potential

Read More

Phase IIa results for diabetic complication drug AS-3201

Read More

Cangene to evaluate WinRho SDF for dengue hemorrhagic fever

Read More

Enrollment completed in phase II study of SPI-0211 for IBS

Read More

NM-100061 produces positive results in early ejaculation study

Read More

Astex Technology joins BRAF drug discovery collaboration

Read More

Aplidin enters phase I for pediatric solid tumors and hematological malignancies

Read More

Siga completes successful smallpox vaccine study

Read More

Pharmacopeia extends and expands research collaboration with Celgene

Read More

OraQuick Rapid HIV-1/2 Antibody Test receives FDA approval

Read More

Protein Mechanics and Aventis enter MMP inhibitor research collaboration

Read More

SBIR grant supports development of novel anti-HIV therapeutics at Aphios

Read More

European filing for Antegren for MS planned for summer

Read More

Proteome Sciences licenses biomarkers for Alzheimer's disease

Read More

HuMax-CD4 receives fast track designation for cutaneous T-cell lymphoma

Read More

Pharmexa shifts strategic focus from research to development

Read More

Ligand reports progress during 2003

Read More

Antidepressant and anxiolytic potential of MGS-0039, a potent, selective group II mGluR antagonist

Read More

Chronic administration of (-)-BPAP may be effective against stress disorders

Read More

Potent neuroprotective effects of FR-210575, a powerful free radical scavenger

Read More

Popular Stories

  • Today's news in brief

    BioWorld
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing